Related resources
Full-text held externally
Search for item elsewhere
University researcher(s)
Academic department(s)
The neoadjuvant approach in the treatment of patients with advanced epithelial ovarian carcinoma.
Rosa, D, Ton, N, Clamp, A, Mullamitha, S, Lau, S, Clayton, R, Kitchener, HC, Shanks, J, McVey, R, Jayson, G-
Clin Oncol (R Coll Radiol). 2007;19(2):125-128.
Access to files
Full-text and supplementary files are not available from Manchester eScholar. Full-text is available externally using the following links:
Full-text held externally
Abstract
AIMS: Ovarian cancer has a very poor prognosis, with 5-year survival rates of 5-20% for advanced-stage disease. This work was designed to verify whether the neoadjuvant approach had an effect on survival in patients with advanced-stage ovarian cancer. MATERIALS AND METHODS: Patients with stage III or IV disease who received neoadjuvant platinum-based chemotherapy (group 1) were compared with a group of conventionally treated patients (group 2). RESULTS: Most of the patients in group 1 (76%) had partial tumoral responses after chemotherapy. Patients from group 1 (n = 42) had a median survival that was not different from that in patients from group 2 (n = 348). Patients who received platinum-based chemotherapy with taxanes had the same survival of patients who received no taxanes. CONCLUSIONS: Our results showed similar responses and survival rates for patients with stage III or IV ovarian cancer treated with neoadjuvant platinum-based chemotherapy, when compared with patients who underwent primary suboptimal cytoreductive surgery. Our data therefore support the ongoing trials to determine the optimum timing of surgery for ovarian cancer.
Keyword(s)
Adult; Aged; Aged, 80 and over; Chemotherapy, Adjuvant; Female; Follow-Up Studies; Humans; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Prognosis; Retrospective Studies; Survival Rate; Time Factors; Treatment Outcome; administration & dosage: Organoplatinum Compounds; administration & dosage: Taxoids; drug therapy: Neoplasms, Glandular and Epithelial; drug therapy: Ovarian Neoplasms; therapeutic use: Antineoplastic Combined Chemotherapy Protocols